Newsroom | 23158 results

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2025. First Half of 2025 Financial Summary Sales for the six months ended June 30, 2025 were $130.3 million, compared to $128.7 million in the prior year period. The Company posted $21.7 million of net loss attributable to common shareholders, or a loss of $0.30 per...

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced the presentation of initial clinical data from the first participant dosed in its Phase 1/2 trial of EN-374 for the treatment of X-linked chronic granulomatous disease (X-CGD) at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11-15 in Boston. The data represent the first reported clini...

GOLDEN, Colorado--(BUSINESS WIRE)--PharmaJet, leader mondial de la technologie d’injection sans aiguille, a annoncé aujourd’hui que son système d’injection ID sans aiguille Tropis, préqualifié par l’OMS, sera utilisé pour administrer environ 1,4 million de doses de vaccin antipoliomyélitique inactivé fractionné (fIPV) lors des prochaines campagnes de vaccination contre la poliomyélite au Nigeria. PharmaJet s’associe au Réseau africain d’épidémiologie de terrain (AFENET) pour déployer Tropis afi...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings. A webcast can be accessed on the Investors section of t...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million; Returned to positive free cash flow, generating $4.2 million in the quarter; and Inc...

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a private TechBio company building programmable platforms to decode, program, and resolve diseases, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 12,618,795 B2, covering Asymmetric Semi-Nested Isothermal Nucleotide Amplification (ANINA), a key assay design component of the company’s nucleic acid amplification chemistry for use in molecular diagnostic systems, called Seek Amplification™. Molecular diagnostics...

GOLDEN, Colo.--(BUSINESS WIRE)--With over 20 million Tropis ID injections supplied globally, PharmaJet is making important contributions to the Global Polio Eradication Initiative....

PHILADELPHIA--(BUSINESS WIRE)--Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company, announced financial and operational highlights for the fiscal quarter ended March 31, 2026. The Company reported net product revenue of approximately $44.2 million during the three months ended March 31, 2026, with net product revenue growth in every quarter since ANKTIVA’s commercial launch, including a 168% increase over Q1 2025. This builds on full-year 2025 net product revenue of $113.0 million,...

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2026. First quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS f...